HTF Market Intelligence released a new research report of 202 pages on title ‘Osteoarthritis Pain – Pipeline Review, H1 2017’ with detailed analysis, forecast and strategies.
Osteoarthritis Pain – Pipeline Review, H1 2017
Global Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Osteoarthritis Pain – Pipeline Review, H1 2017, provides an overview of the Osteoarthritis Pain (Central Nervous System) pipeline landscape.
Osteoarthritis pain is the most common symptom associated with osteoarthritis which causes disruption of the cartilage. This further leads to rubbing of the bones against each other stimulating pain. The predisposing factors are age, joint injury, obesity and heredity. It may be diagnosed by physical examination and MRI and X-ray imaging. The condition may be controlled by weight control, exercise and medication.
Request a sample report @ https://www.htfmarketreport.com/sample-report/398212-osteoarthritis-pain-pipeline-review
Global Markets Direct’s Pharmaceutical and Healthcare latest pipeline guide Osteoarthritis Pain – Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Osteoarthritis Pain (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Osteoarthritis Pain (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Osteoarthritis Pain and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 6, 22, 5, 1, 22 and 3 respectively. Similarly, the Universities portfolio in Phase II and Discovery stages comprises 1 and 1 molecules, respectively.
Osteoarthritis Pain (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
– The pipeline guide provides a snapshot of the global therapeutic landscape of Osteoarthritis Pain (Central Nervous System).
– The pipeline guide reviews pipeline therapeutics for Osteoarthritis Pain (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
– The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
– The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
– The pipeline guide reviews key companies involved in Osteoarthritis Pain (Central Nervous System) therapeutics and enlists all their major and minor projects.
– The pipeline guide evaluates Osteoarthritis Pain (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
– The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
– The pipeline guide reviews latest news related to pipeline therapeutics for Osteoarthritis Pain (Central Nervous System)
Reasons to buy
– Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
– Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
– Find and recognize significant and varied types of therapeutics under development for Osteoarthritis Pain (Central Nervous System).
– Classify potential new clients or partners in the target demographic.
– Develop tactical initiatives by understanding the focus areas of leading companies.
– Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
– Formulate corrective measures for pipeline projects by understanding Osteoarthritis Pain (Central Nervous System) pipeline depth and focus of Indication therapeutics.
– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
– Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Companies Mentioned in the Report
Addex Therapeutics Ltd
Ampio Pharmaceuticals Inc
Antibe Therapeutics Inc
Aralez Pharmaceuticals Inc
Arena Pharmaceuticals Inc
Array BioPharma Inc
Astellas Pharma Inc
Axsome Therapeutics Inc
BELLUS Health Inc
Boehringer Ingelheim GmbH
Cara Therapeutics Inc
Eli Lilly and Company
Elite Pharmaceuticals Inc
Eupraxia Pharmaceuticals Inc
Flexion Therapeutics Inc
Iroko Pharmaceuticals LLC
Marina Biotech Inc
Medestea Research & Production SpA
Merck & Co Inc
Nuvo Pharmaceuticals Inc
Ono Pharmaceutical Co Ltd
Purdue Pharma LP
Regeneron Pharmaceuticals Inc
Rottapharm Biotech Srl
Shionogi & Co Ltd
Symic Biomedical Inc
Taiwan Liposome Company Ltd
Vertex Pharmaceuticals Inc
Zynerba Pharmaceuticals Inc
Make an enquiry before buying this Report @ https://www.htfmarketreport.com/enquiry-before-buy/398212-osteoarthritis-pain-pipeline-review
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 6
Global Markets Direct Report Coverage 7
Osteoarthritis Pain – Overview 8
Osteoarthritis Pain – Therapeutics Development 9
Pipeline Overview 9
Pipeline by Companies 10
Pipeline by Universities/Institutes 14
Products under Development by Companies 15
Products under Development by Universities/Institutes 19
Osteoarthritis Pain – Therapeutics Assessment 20
Assessment by Target 20
Assessment by Mechanism of Action 23
Assessment by Route of Administration 26
Assessment by Molecule Type 28
Osteoarthritis Pain – Companies Involved in Therapeutics Development 30
AbbVie Inc 30
Addex Therapeutics Ltd 30
Allergan Plc 31
Ampio Pharmaceuticals Inc 31
Antibe Therapeutics Inc 32
Aralez Pharmaceuticals Inc 32
Arena Pharmaceuticals Inc 33
Array BioPharma Inc 33
Astellas Pharma Inc 34
Axsome Therapeutics Inc 34
BELLUS Health Inc 35
Boehringer Ingelheim GmbH 35
Cara Therapeutics Inc 36
Chromocell Corp 36
Eli Lilly and Company 37
Elite Pharmaceuticals Inc 37
Eupraxia Pharmaceuticals Inc 38
Flexion Therapeutics Inc 38
Genzyme Corp 39
GlaxoSmithKline Plc 39
Grunenthal GmbH 40
Iroko Pharmaceuticals LLC 40
Marina Biotech Inc 41
Medestea Research & Production SpA 41
MedImmune LLC 42
Merck & Co Inc 42
Nuvo Pharmaceuticals Inc 43
Ono Pharmaceutical Co Ltd 43
Pfizer Inc 44
Phosphagenics Ltd 44
ProteoThera Inc 45
pSivida Corp 45
Purdue Pharma LP 46
Regeneron Pharmaceuticals Inc 46
Rottapharm Biotech Srl 47
Shionogi & Co Ltd 47
Symic Biomedical Inc 48
Taiwan Liposome Company Ltd 48
Vertex Pharmaceuticals Inc 49
Zynerba Pharmaceuticals Inc 49
Osteoarthritis Pain – Drug Profiles 50
(amlodipine besylate + celecoxib) – Drug Profile 50
(celecoxib + lisinopril) – Drug Profile 54
View Detailed Table of Content @ https://www.htfmarketreport.com/reports/398212-osteoarthritis-pain-pipeline-review
Buy this report @ https://www.htfmarketreport.com/buy-now?format=1&report=398212
CRAIG FRANCIS (PR & Marketing Manager)
Ph: +1 (206) 317 1218